AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Moderna Inc (NASDAQ:MRNA)
33.905 USD
-1.245 3.542%Sponsored Reports
Loading...
| Previous Close (in USD) | 35.15 |
|---|---|
| Change | -1.245 3.542% |
| 52 W H/L (in USD) | 170.470/62.550 |
| EBITDA (in USD) | -4560M |
| PE Ratio | -- |
| Volume | 7365886 |
| Diluted Eps TTM | -15.59 |
| Total Assets (in USD) | 18426M |
|---|---|
| Total Liabilities (in USD) | 4572M |
| Revenue TTM (in USD) | 5153M |
| Cash (in USD) | 2907M |
| Market Cap (in USD) | 58,712.367 M |
| Revenue Per Share TTM | 13.525 |
| Gross Profit TTM (in USD) | 10552M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Moderna Inc
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Employees: 5600
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Noubar B. Afeyan Ph.D. | Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board | 1963 |
| 2. | Mr. Stephane Bancel | CEO & Director | 1973 |
| 3. | Dr. Stephen Hoge M.D. | Pres | 1976 |
| 4. | Ms. Shannon Thyme Klinger | Chief Legal Officer & Corp. Sec. | 1971 |
| 5. | Mr. Juan Andres | Pres of Strategic Partnerships & Enterprise Expansion | 1965 |
| 6. | Mr. James M. Mock | Chief Financial Officer | 1977 |
| 7. | Dr. Jerh Collins Ph.D. | Chief Technical Operations & Quality Officer | NA |
| 8. | Dr. John V. W. Reynders Ph.D. | Chief Information Officer | NA |
| 9. | Dr. Melissa J. Moore Ph.D. | Chief Scientific Officer & Member of Scientific Advisory Board | NA |
| 10. | Ms. Lavina Talukdar CFA | Sr. VP & Head of Investor Relations | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-3.705 4.378% | 82.92 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-2.800 3.343% | 81.71 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+1.130 0.273% | 411.94 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-18.615 2.597% | 714.01 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 9575M | 13285M | -744.513M | -514.716M | -384.408M |
| Minority Interest | - | - | - | - | - |
| Net Income | 8362M | 12202M | -747.064M | -514.021M | -384.734M |
| Selling General Administrative | 1132M | 567M | 188.267M | 109.62M | 94.252M |
| Gross Profit | 13847M | 15119M | 266.557M | 48.036M | 135.068M |
| Reconciled Depreciation | 348M | 232M | 31.251M | 31.021M | 24.862M |
| Ebit | 9420M | 13064M | -794.395M | -576.741M | -438.128M |
| Ebitda | 9768M | 13296M | -763.144M | -545.72M | -413.266M |
| Depreciation And Amortization | 348M | 232M | 31.251M | 31.021M | 24.862M |
| Operating Income | 9420M | 13296M | -763.144M | -545.72M | -413.266M |
| Other Operating Expenses | 9843M | 4440M | 1037.634M | 593.756M | 535.778M |
| Interest Expense | 29M | 18M | 9.886M | 6.612M | 0M |
| Tax Provision | 1213M | 1083M | 2.551M | -0.695M | 0.326M |
| Interest Income | 200M | 18M | 24.715M | 38.53M | 27.023M |
| Net Interest Income | 200M | 18M | 14.829M | 31.918M | 27.023M |
| Income Tax Expense | 1213M | 1083M | 2.551M | -0.695M | 0.326M |
| Total Revenue | 19263M | 17736M | 274.49M | 48.036M | 122.512M |
| Total Operating Expenses | 4427M | 1823M | 1029.701M | 593.756M | 535.778M |
| Cost Of Revenue | 5416M | 2617M | 7.933M | 496.309M | -12.556M |
| Total Other Income Expense Net | 155M | -11M | 18.631M | 31.004M | 1.835M |
| Net Income From Continuing Ops | 8362M | 12202M | -747.064M | -514.021M | -384.734M |
| Net Income Applicable To Common Shares | 8362M | 12202M | -747.064M | -514.021M | -401.857M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 18426M | 25858M | 24669M | 7336.75M | 1589.422M |
| Intangible Assets | 44M | - | - | - | - |
| Other Current Assets | 88M | 1195M | 55M | -405.631M | 887.896M |
| Total Liab | 4572M | 6735M | 10524M | 4775.375M | 414.612M |
| Total Stockholder Equity | 13854M | 19123M | 14145M | 2561.375M | 1174.81M |
| Other Current Liab | 1902M | 2202M | 2362M | 33.665M | 5.063M |
| Common Stock | - | - | -857M | 0.04M | 0.034M |
| Capital Stock | 0M | 0M | 0M | 0.04M | 0.034M |
| Retained Earnings | 13606M | 18320M | 9958M | -2243.518M | -1496.454M |
| Good Will | 52M | - | - | - | - |
| Other Assets | - | 1928M | 7383M | 741.982M | 12.722M |
| Cash | 2907M | 3205M | 6848M | 2623.85M | 235.876M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 3015M | 4923M | 9128M | 4388.808M | 143.115M |
| Current Deferred Revenue | 568M | 2038M | 6253M | 3867.193M | 63.31M |
| Net Debt | -1664M | -2005M | -5932M | -2416.555M | -103.512M |
| Short Term Debt | 25M | 196M | 211M | 469.591M | 67.652M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 1243M | 1200M | 916M | 207.295M | 132.364M |
| Other Stockholder Equity | 371M | 1173M | 4211M | 4801.849M | 2669.426M |
| Property Plant Equipment | - | 2139M | 1383M | 387.09M | 287.909M |
| Total Current Assets | 10325M | 13431M | 17570M | 6297.879M | 1262.987M |
| Long Term Investments | 4743M | 8318M | 6843M | 638.848M | 159.987M |
| Short Term Investments | 5697M | 6697M | 3879M | 1983.758M | 867.124M |
| Net Receivables | 1081M | 1385M | 3296M | 1410.527M | 16.297M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 202M | 949M | 1441M | 46.527M | -904.193M |
| Accounts Payable | 520M | 487M | 302M | 18.359M | 7.09M |
| Accumulated Other Comprehensive Income | -123M | -370M | -24M | 3.004M | 1.804M |
| Non Currrent Assets Other | 523M | 988M | 46M | 12.933M | -121.461M |
| Non Current Assets Total | 8101M | 12427M | 7099M | 1038.871M | 326.435M |
| Capital Lease Obligations | 1243M | 1004M | 916M | 207.295M | 132.364M |
| Long Term Debt Total | - | - | - | - | 38.689M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -5176M | -8239M | -1604.48M | 16.609M | -267.328M |
| Total Cashflows From Investing Activities | -5176M | -8523M | -1671.928M | -14.945M | -372.472M |
| Total Cash From Financing Activities | -3448M | -873M | 2033.193M | 51.121M | 1226.842M |
| Net Income | 8362M | 12202M | -747.064M | -514.021M | -384.734M |
| Change In Cash | -3643M | 4224M | 2388.236M | -422.792M | 523.505M |
| Begin Period Cash Flow | 6860M | 2636M | 247.699M | 670.491M | 134.859M |
| End Period Cash Flow | 3217M | 6860M | 2635.935M | 247.699M | 658.364M |
| Total Cash From Operating Activities | 4981M | 13620M | 2026.971M | -458.968M | -330.865M |
| Depreciation | 348M | 232M | 31.251M | 31.021M | 24.862M |
| Other Cashflows From Investing Activities | -40M | -30M | -30M | 16.609M | 0.622M |
| Dividends Paid | - | -124M | -7.04M | - | - |
| Change To Inventory | 492M | -1394M | -46.527M | 7.203M | 4.408M |
| Sale Purchase Of Stock | -3329M | -857M | 7.04M | 2.891M | -8.182M |
| Other Cashflows From Financing Activities | -184M | 124M | 186.683M | 0.971M | 674.173M |
| Capital Expenditures | 400M | 284M | 67.448M | 31.554M | 105.766M |
| Change In Working Capital | -3455M | 990M | 2577.054M | -53.664M | -42.583M |
| Other Non Cash Items | 59M | 372M | 62.286M | -3.426M | -0.975M |
| Free Cash Flow | 4581M | 13336M | 1959.523M | -490.522M | -436.631M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Performer (AFRIS) | 10 months ago | 47597385 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 8 months ago | 10782206 |
| 3. | Scottish Mortgage Ord | 9 months ago | 9203081 |
| 4. | Vanguard International Growth Inv | 9 months ago | 9151211 |
| 5. | Vanguard Institutional 500 Index Trust | 8 months ago | 8439868 |
| 6. | Vanguard Mid Cap Index Institutional | 8 months ago | 7469649 |
| 7. | Invesco QQQ Trust | 8 months ago | 7179652 |
| 8. | Vanguard Health Care Inv | 9 months ago | 5023937 |
| 9. | Fidelity 500 Index | 9 months ago | 4009025 |
| 10. | SPDR® S&P 500 ETF Trust | 8 months ago | 3917642 |
| 11. | AF High Growth (AFRIS) | 10 months ago | 3617838 |
| 12. | iShares Core S&P 500 ETF | 8 months ago | 3416229 |
| 13. | Vanguard Growth Index Investor | 8 months ago | 3316596 |
| 14. | Baillie Gifford US Equity Growth | 9 months ago | 2904355 |
| 15. | Vanguard US Growth Investor | 9 months ago | 2904355 |
| 16. | American Funds Growth Fund of Amer A | 9 months ago | 2682932 |
| 17. | Capital Group Growth Fnd of Amer Comp | 9 months ago | 2682932 |
| 18. | UBS: Global Equity | 1 year ago | 2514274 |
| 19. | iShares Biotechnology ETF | 8 months ago | 2484834 |
| 20. | Vanguard Mid-Cap Growth ETF | 8 months ago | 2459975 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Baillie Gifford & Co Limited. | 9 months ago | 44655817 |
| 2. | Vanguard Group Inc | 9 months ago | 39036872 |
| 3. | BlackRock Inc | 1 year ago | 25301692 |
| 4. | State Street Corporation | 1 year ago | 14623723 |
| 5. | Flagship Ventures Management, Inc. | 9 months ago | 9666038 |
| 6. | Goldman Sachs Group Inc | 1 year ago | 9103252 |
| 7. | Theleme Partners LLP | 9 months ago | 7321797 |
| 8. | Wellington Management Company LLP | 1 year ago | 7225579 |
| 9. | Geode Capital Management, LLC | 1 year ago | 6549461 |
| 10. | FMR Inc | 1 year ago | 6393351 |
| 11. | Morgan Stanley - Brokerage Accounts | 1 year ago | 4389108 |
| 12. | UBS Asset Mgmt Americas Inc | 9 months ago | 3673043 |
| 13. | Capital World Investors | 9 months ago | 3648117 |
| 14. | Manufacturers Life Insurance Co | 1 year ago | 3542967 |
| 15. | NORGES BANK | 1 year ago | 3494874 |
| 16. | Banque Pictet & Cie SA | 9 months ago | 3161729 |
| 17. | Northern Trust Corp | 1 year ago | 2971996 |
| 18. | Amvescap Plc. | 1 year ago | 2909609 |
| 19. | Legal & General Group PLC | 1 year ago | 2830894 |
| 20. | Pictet Asset Manangement SA | 9 months ago | 2621637 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
